SG10201803294PA - Tau imaging probe - Google Patents
Tau imaging probeInfo
- Publication number
- SG10201803294PA SG10201803294PA SG10201803294PA SG10201803294PA SG10201803294PA SG 10201803294P A SG10201803294P A SG 10201803294PA SG 10201803294P A SG10201803294P A SG 10201803294PA SG 10201803294P A SG10201803294P A SG 10201803294PA SG 10201803294P A SG10201803294P A SG 10201803294PA
- Authority
- SG
- Singapore
- Prior art keywords
- tau
- imaging probe
- low
- tau imaging
- none
- Prior art date
Links
- 238000003384 imaging method Methods 0.000 title abstract 2
- 239000000523 sample Substances 0.000 title abstract 2
- 210000004556 brain Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 230000007704 transition Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B57/00—Separation of optically-active compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Optics & Photonics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
TAU IMAGING PROBE An obj ect of the present invention is to provide a compound represented by formula (I) which is highly specific to tau and can image tau with satisfactory sensitivity, and also has high brain transition, low or non-recognized bone-seeking properties and low or undetected toxicity. 10 (1) Figure for publication: None 173
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013233470 | 2013-10-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201803294PA true SG10201803294PA (en) | 2018-06-28 |
Family
ID=52992954
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201603131RA SG11201603131RA (en) | 2013-10-22 | 2014-10-22 | Tau imaging probe |
SG10201803294PA SG10201803294PA (en) | 2013-10-22 | 2014-10-22 | Tau imaging probe |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201603131RA SG11201603131RA (en) | 2013-10-22 | 2014-10-22 | Tau imaging probe |
Country Status (13)
Country | Link |
---|---|
US (1) | US20160244411A1 (en) |
EP (1) | EP3061748A4 (en) |
JP (1) | JPWO2015060365A1 (en) |
KR (1) | KR20160072226A (en) |
CN (1) | CN105814023A (en) |
AU (1) | AU2014338155B2 (en) |
BR (1) | BR112016008871A8 (en) |
CA (1) | CA2928313A1 (en) |
IL (1) | IL245221A0 (en) |
MX (1) | MX2016005233A (en) |
RU (1) | RU2016119524A (en) |
SG (2) | SG11201603131RA (en) |
WO (1) | WO2015060365A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201522414D0 (en) * | 2015-12-18 | 2016-02-03 | Clino Ltd | Monoamine oxidase B binders |
EP3484528B1 (en) * | 2016-07-18 | 2020-11-25 | Janssen Pharmaceutica NV | Tau pet imaging ligands |
EP3652329B1 (en) * | 2017-07-12 | 2023-10-04 | Dana-Farber Cancer Institute, Inc. | Compounds for tau protein degradation |
CN107488144B (en) * | 2017-08-09 | 2021-06-04 | 复旦大学 | Molecule capable of specifically binding and inhibiting Tau protein aggregation and preparation method and application thereof |
JP7284490B2 (en) | 2018-08-07 | 2023-05-31 | 国立大学法人東北大学 | Monoamine oxidase B imaging probe |
KR20210128125A (en) * | 2020-04-16 | 2021-10-26 | 연세대학교 산학협력단 | A Contrast Agent Composition for Detecting Lesional Margin of Dementia Caused by Degenerative Brain Disease Comprising Quinoline Derivatives as Active Ingredients |
KR102369838B1 (en) * | 2020-04-16 | 2022-03-04 | 연세대학교 산학협력단 | A Contrast Agent Composition for Detecting Lesional Margin of Astrocytosis-Related Disease Comprising Quinoline Derivatives as Active Ingredients |
CN111892534A (en) * | 2020-08-04 | 2020-11-06 | 中国科学技术大学 | pH-sensitive fluorescent probe, and preparation method and application thereof |
CN113754583A (en) * | 2021-09-03 | 2021-12-07 | 湖南工程学院 | 2- ([2, 2' -biquinolyl ] -3-ether) -1-ethanol and derivative and synthetic method thereof |
CN113999172A (en) * | 2021-11-17 | 2022-02-01 | 湖南工程学院 | 2- ((2-phenylquinoline-3-yl) ether) -1-ethanol and derivative and synthetic method thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1574500A1 (en) | 2002-12-16 | 2005-09-14 | BF Research Institute, Inc. | Quinoline derivative as diagnostic probe for disease with tau protein accumulation |
US8483197B2 (en) * | 2009-03-23 | 2013-07-09 | Qualcomm Incorporated | AP to legacy station SDMA protocol |
US8691187B2 (en) * | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
EP2411057B1 (en) * | 2009-03-23 | 2020-05-06 | Eli Lilly and Company | Imaging agents for detecting neurological disorders |
KR101101977B1 (en) | 2009-04-09 | 2012-01-02 | (주)에스메디 | 2-aryl naphthalene, 2-aryl quinoline derivatives or pharmaceutically acceptable salts thereof, preparation method thereof, and phrmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as an active ingredient |
WO2012057312A1 (en) * | 2010-10-29 | 2012-05-03 | クリノ株式会社 | Tau imaging probe |
RU2013125326A (en) * | 2010-11-16 | 2014-12-27 | ДжиИ ХЕЛТКЕР ЛИМИТЕД | HETEROCYCLIC COMPOUNDS AS PROBES FOR VISUALIZING TAU PATHOLOGY |
GB201411571D0 (en) * | 2014-06-30 | 2014-08-13 | Ge Healthcare Ltd | Radiolabelling method |
-
2014
- 2014-10-22 CN CN201480070144.2A patent/CN105814023A/en active Pending
- 2014-10-22 SG SG11201603131RA patent/SG11201603131RA/en unknown
- 2014-10-22 JP JP2015543896A patent/JPWO2015060365A1/en active Pending
- 2014-10-22 SG SG10201803294PA patent/SG10201803294PA/en unknown
- 2014-10-22 US US15/030,924 patent/US20160244411A1/en not_active Abandoned
- 2014-10-22 EP EP14855618.6A patent/EP3061748A4/en not_active Withdrawn
- 2014-10-22 CA CA2928313A patent/CA2928313A1/en not_active Abandoned
- 2014-10-22 AU AU2014338155A patent/AU2014338155B2/en not_active Ceased
- 2014-10-22 KR KR1020167013070A patent/KR20160072226A/en not_active Application Discontinuation
- 2014-10-22 RU RU2016119524A patent/RU2016119524A/en not_active Application Discontinuation
- 2014-10-22 WO PCT/JP2014/078146 patent/WO2015060365A1/en active Application Filing
- 2014-10-22 MX MX2016005233A patent/MX2016005233A/en unknown
- 2014-10-22 BR BR112016008871A patent/BR112016008871A8/en not_active Application Discontinuation
-
2016
- 2016-04-20 IL IL245221A patent/IL245221A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2015060365A1 (en) | 2015-04-30 |
EP3061748A1 (en) | 2016-08-31 |
RU2016119524A (en) | 2017-11-28 |
EP3061748A4 (en) | 2017-04-05 |
AU2014338155A1 (en) | 2016-05-19 |
SG11201603131RA (en) | 2016-05-30 |
IL245221A0 (en) | 2016-06-30 |
US20160244411A1 (en) | 2016-08-25 |
JPWO2015060365A1 (en) | 2017-03-09 |
AU2014338155B2 (en) | 2018-08-23 |
BR112016008871A8 (en) | 2020-03-24 |
RU2016119524A3 (en) | 2018-06-14 |
MX2016005233A (en) | 2017-01-05 |
CA2928313A1 (en) | 2015-04-30 |
CN105814023A (en) | 2016-07-27 |
KR20160072226A (en) | 2016-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201803294PA (en) | Tau imaging probe | |
EA201890899A1 (en) | PHARNESIDE X-RECEPTOR MODULATORS | |
IN2015MN00404A (en) | ||
MY180083A (en) | Tetrahydropyrrolothiazine compounds | |
IN2015MN00405A (en) | ||
MX2016014615A (en) | Deuterated heterocyclic compounds and their use as imaging agents. | |
MA38583B1 (en) | Derivatives of dolastatin 10 and auristatines | |
CR20140468A (en) | DIACILGLICEROL ACILTRANSFERASA 2 INHIBITORS | |
EA201591503A1 (en) | NAFTHYRIDINE DERIVATIVES, USEFUL AS ANTAGONISTS ALPHA-V-BETA-6 INTEGRINA | |
BR112016011755A2 (en) | derived from urea or pharmacologically acceptable salt thereof | |
RS54730B1 (en) | Inhibitors of beta-secretase | |
CY1118883T1 (en) | METHOD OF PREPARATION OF BORTIOXETINE | |
RS54526B1 (en) | Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors | |
PH12019501178A1 (en) | Thiopene derivatives as antiviral agents | |
IN2015DN02930A (en) | ||
CR20140306A (en) | FLUORMETIL -5,6-DIHIDRO-4H- [1,3] OXAZINES | |
SG10201805896SA (en) | PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS | |
EA201591815A1 (en) | BICYCLO [2.2.2] ACIDS - GPR120 MODULATORS | |
JOP20200030A1 (en) | Pentacyclic compound | |
AR095097A1 (en) | PHENOXYETOXI COMPOUNDS | |
NZ731607A (en) | Dihydropyrimidin-2- one compounds and medical use thereof | |
IN2013MU03862A (en) | ||
BR112015023270A2 (en) | polycyclic pyrazolinone derivative and herbicide comprising the same as an effective component | |
UY37443A (en) | PHENYLAMINE DERIVATIVES REPLACED IN POSITION 4 AND USE OF THE SAME TO PROTECT CROPS BY COMBATING UNWANTED PHYTOOPATHOGEN MICROORGANISMS | |
EP3769757A3 (en) | Imaging histone deacetylases with a radiotracer using positron emission tomography |